Free Trial
NYSE:NVS

Novartis (NVS) Stock Price, News & Analysis

Novartis logo
$161.80 +1.31 (+0.81%)
As of 12:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Novartis Stock (NYSE:NVS)

Advanced

Key Stats

Today's Range
$161.49
▼
$163.27
50-Day Range
$137.22
▼
$164.98
52-Week Range
$123.24
▼
$170.46
Volume
745,782 shs
Average Volume
2.00 million shs
Market Capitalization
$308.75 billion
P/E Ratio
30.87
Dividend Yield
1.90%
Price Target
$152.25
Consensus Rating
Hold

Company Overview

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health.

The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

Novartis was formed in 1996 through the merger of Swiss companies Ciba-Geigy and Sandoz. In 2023, it completed the spin-off of its generics and biosimilars business, Sandoz, and now focuses on innovative medicines. Headquartered in Basel, Switzerland, Novartis serves patients and healthcare systems in markets around the world.

AI Generated. May Contain Errors.

Novartis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

NVS MarketRank™: 
3.105688900675 of 5 stars

Novartis scored higher than 62% of companies evaluated by MarketBeat, and ranked 327th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novartis has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 6 buy ratings, 9 hold ratings, and 3 sell ratings.

  • Downside Risk

    Novartis has a consensus price target of $152.25, representing about 5.7% downside from its current price of $161.50.

  • Amount of Analyst Coverage

    Novartis has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Novartis' stock forecast and price target.
  • Earnings Growth

    Earnings for Novartis are expected to grow by 9.78% in the coming year, from $9.10 to $9.99 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novartis is 30.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.22.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novartis is 30.84, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.45.

  • Price to Earnings Growth Ratio

    Novartis has a PEG Ratio of 2.94. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novartis has a P/B Ratio of 7.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Novartis' valuation and earnings.
  • Percentage of Shares Shorted

    0.24% of the float of Novartis has been sold short.
  • Short Interest Ratio / Days to Cover

    Novartis has a short interest ratio ("days to cover") of 1.89, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novartis has recently decreased by 19.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Novartis pays a meaningful dividend of 1.92%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novartis does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novartis is 58.78%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Novartis will have a dividend payout ratio of 30.83% next year. This indicates that Novartis will be able to sustain or increase its dividend.

  • Read more about Novartis' dividend.
  • News Sentiment

    Novartis has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Novartis this week, compared to 10 articles on an average week.
  • Search Interest

    Only 6 people have searched for NVS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Novartis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.01% of the stock of Novartis is held by insiders.

  • Percentage Held by Institutions

    13.12% of the stock of Novartis is held by institutions.

  • Read more about Novartis' insider trading history.
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVS Stock News Headlines

Novartis Stock Gets Weaker EPS Estimate from Zacks Research
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Novartis (NVS) Stock Forecast & Price Target
Novartis FY2026 Earnings Forecast Boosted by Zacks Research
See More Headlines

NVS Stock Analysis - Frequently Asked Questions

Novartis' stock was trading at $137.87 at the beginning of 2026. Since then, NVS stock has increased by 17.1% and is now trading at $161.4950.

Novartis AG (NYSE:NVS) released its quarterly earnings data on Tuesday, October, 27th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.25 by $0.21. The business's revenue for the quarter was up 4.4% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Novartis: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more.

Novartis' top institutional shareholders include Fisher Asset Management LLC (0.88%), Cullen Capital Management LLC (0.10%), Dodge & Cox (0.04%) and First Trust Advisors LP (0.02%).

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), NVIDIA (NVDA), AbbVie (ABBV), Intel (INTC) and Cisco Systems (CSCO).

Company Calendar

Last Earnings
10/27/2026
Today
11/16/2026
Meet Novartis Management 2026 Part 1
11/19/2026
Meet Novartis Management 2026 Part 2
11/19/2026
Meet Novartis Management 2026 Part 3
11/19/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
2/03/2027

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:NVS
CIK
1114448
Employees
75,267
Year Founded
1996

Price Target and Rating

High Price Target
$180.00
Low Price Target
$130.00
Potential Upside/Downside
-5.9%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
$5.24
Trailing P/E Ratio
30.91
Forward P/E Ratio
16.19
P/E Growth
2.94
Net Income
$13.98 billion
Net Margins
18.11%
Pretax Margin
22.83%
Return on Equity
41.04%
Return on Assets
14.45%

Debt

Debt-to-Equity Ratio
0.98
Current Ratio
0.88
Quick Ratio
0.70

Sales & Book Value

Annual Sales
$54.53 billion
Price / Sales
5.66
Cash Flow
$10.83 per share
Price / Cash Flow
14.94
Book Value
$22.04 per share
Price / Book
7.34

Miscellaneous

Outstanding Shares
1,908,150,000
Free Float
1,907,961,000
Market Cap
$308.69 billion
Optionable
Optionable
Beta
0.40

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NYSE:NVS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners